Skip to main content

Greenberg Bruce's Form 4/A amendment

Amended

Aldeyra Therapeutics, Inc.ALDX · filed Apr 17, 2024

Accession no.
0000950170-24-045108
Filed
Apr 17, 2024
Trade date
Mar 11, 2024
Filing delay
37 days
Rule 10b5-1 plan
Not checked
Original filed
Mar 12, 2024

This filing lists 1 non-derivative transaction. It carries over 1 transaction from the original filing that it did not restate. Open-market sales total $45.0K. It was filed 37 days after the trade.

This amendment restates part of 0000950170-24-030314 (filed Mar 12, 2024). The transactions it did not restate still count and are listed below.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Greenberg BruceCIK 0001928391Officer (See Remarks)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Mar 11, 2024Common StockSSaleDisposed−13,201$3.41F2−$45,015.41130,154Direct

Carried over from the original filing

This amendment restates only part of the original filing. The original's other transactions still stand, and the trade tables on Livermore count them under this amendment.

From 0000950170-24-030314 (filed Mar 12, 2024).

Derivative securities (Table II)

Derivative transactions carried over from 0000950170-24-030314
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Mar 9, 2024Common StockAGrant or awardAcquired+252,280$0.00$0252,280Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the settlement of certain time-based restricted stock unit awards. This sale was previously reported in the Reporting Person's Form 4 filed on March 12, 2024 (the "Original Form 4").

F2

Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $3.27 to $3.58. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

Referenced by the price of 1 transaction in Table I.

F3

Adjusted to reflect 9,455 shares of common stock acquired under the Issuer's Employee Stock Purchase Plan, which were inadvertently omitted in the Original Form 4. The amount in Column 5 of this Form 4 reflects the number of shares beneficially owned by the Reporting Person as of the date of this report after giving effect to the adjustment.

Remarks

Interim Chief Financial Officer

Read the full filing on SEC EDGAR (opens in a new tab)